Global Positron Emission Tomography Market Size Study and Forecast by Product Type, By Modality, By Radiotracer/Isotope, By Application, By End User, and Regional Forecasts 2026-2036

Global Positron Emission Tomography (PET) Market Definition & Scope

The Global Positron Emission Tomography (PET) Market, valued at USD 1.13 Billion in 2025, is projected to reach USD 1.67 Billion by 2036, expanding at a CAGR of 3.61% during the forecast period. Positron emission tomography is a highly advanced nuclear imaging modality that allows visualization of physiological and metabolic processes at a molecular level, enabling early detection of diseases, accurate diagnosis, treatment planning and therapy monitoring. The market comprises full-ring and partial-ring PET scanners, integrated imaging modalities such as stand-alone PET, PET/CT, and PET/MRI, and a range of radiotracers including 18F-FDG, 68Ga-based tracers, cardiac tracers, and immuno-PET isotopes. PET imaging is extensively used in oncology, cardiology, neurology, inflammatory disorders and other clinical applications by hospitals, diagnostic imaging centers and specialized healthcare facilities.

The market is growing steadily due to the increasing incidence of cancer, cardiovascular diseases and neurological disorders, increasing demand for precision diagnostics and continuous technological advancements in hybrid imaging systems and radiopharmaceuticals. The increasing adoption of PET/CT and PET/MRI platforms, along with the increasing use of targeted molecular imaging and novel radiotracers, are dramatically improving diagnostic accuracy and personalized treatment planning. According to the World Health Organization (WHO), cancer still is one of the leading causes of death worldwide . This highlights the importance of advanced molecular imaging technologies for early diagnosis and treatment monitoring. The global positron emission tomography market is expected to witness significant long-term growth opportunities over the forecast period due to ongoing investments in radiopharmaceutical production, artificial intelligence-assisted image reconstruction, digital PET technologies, and precision medicine.

Global Positron Emission Tomography (PET) Market: Key Highlights

• The Global Positron Emission Tomography (PET) Market was valued at USD 1.13 billion in 2025, driven by increasing prevalence of cancer, cardiovascular and neurological disorders, growing demand for molecular imaging and continuous advancements in hybrid diagnostic imaging technologies.
• The market size is estimated to grow to USD 1.67 billion by 2036 at a CAGR of 3.61% during 2026-2036. The growth is attributed to the growing adoption of precision medicine, growing radiopharmaceutical production, AI-based image analysis and increasing use of PET imaging for disease diagnosis and treatment monitoring.
• North America is estimated to account for the largest share of the global market in 2025, at 39.5%. The region is marked by advanced healthcare infrastructure, high adoption of hybrid imaging systems, widespread availability of radiopharmaceuticals, favourable reimbursement policies and strong investment in oncology diagnostics.
• The Asia Pacific is projected to grow at a remunerative CAGR of 4.6% during 2026-2036 driven by the expanding healthcare infrastructure, increasing incidence of cancer, growing investments in diagnostic imaging, rising availability of cyclotrons and radiotracers, and enhanced access to advanced molecular imaging in countries such as China, India, Japan, South Korea, and Southeast Asia.
• Full Ring PET Scanners is the most widely used type which takes up about 72.8% of the total sales in 2025. They are credited with greater image sensitivity, better spatial resolution, faster scan times and broad utilization in hospitals and advanced diagnostic imaging centers.
• The Partial-Ring PET Scanners are estimated to have the fastest CAGR of 4.1% during the forecast period, owing to the growing demand for cost-effective imaging systems, increasing installation in smaller healthcare facilities, and technological advancements in detector design.
• In 2025, the modality segment is expected to be led by the PET/CT segment, with an estimated share of 76.2%. This is attributed to the ability of PET/CT to combine metabolic and anatomic imaging, enabling accurate diagnosis, staging, treatment planning, and disease monitoring in diverse clinical applications.
• PET/MRI is estimated to witness the highest CAGR of 5.3% over the forecast period 2026-2036, owing to its superior soft-tissue imaging, reduced radiation exposure, growing applications in neurological and pediatric imaging, and increasing use in precision oncology.
• The radiotracer segment is dominated by 18F-Fluorodeoxyglucose (18F-FDG) with an estimated share of 68.7% in 2025. This is due to its widespread clinical use in metabolic imaging and disease assessment in the fields of oncology, cardiology and neurology.
• The 68Ga-Based Tracers (DOTATATE & PSMA) are predicted to exhibit the highest CAGR of 6.2% during the forecast period, driven by the rising adoption of targeted molecular imaging for neuroendocrine tumors and prostate cancer, alongside the sustained expansion of theranostic medicine.
• The oncology segment accounts for the largest share of the application segment, with an estimated share of 63.9% in 2025. This is due to the extensive use of PET imaging in cancer detection, staging, treatment response assessment, monitoring of recurrence and planning of personalized therapy.
• The field of neurology is expected to register the fastest CAGR of 4.8% during 2026-2036 on account of increasing prevalence of Alzheimer's disease, Parkinson's disease, epilepsy and other neurodegenerative disorders that require advanced molecular brain imaging.
• Hospitals lead the end-user segment with an estimated share of 66.1% in 2025, owing to large patient volumes, availability of integrated imaging infrastructure, multidisciplinary cancer centers, and higher capital investment in advanced diagnostic technologies.
• Diagnostic Imaging Centres are expected to record the highest CAGR of 4.4% during the forecast period, owing to increased demand for outpatient diagnostic services, expansion of private imaging networks, and enhanced availability of advanced PET imaging technologies.

Research Scope & Methodology

This study provides a comprehensive strategic assessment of the Global Positron Emission Tomography (PET) Market across the forecast period of 2026-2036. The report provides insights into the market size, revenue forecasts, competitive scenario, technological advancements, regulatory updates, radiopharmaceutical innovation, reimbursement trends and emerging investment avenues shaping the global PET imaging industry. The assessment covers the entire value chain: cyclotron manufacturing, radioisotope production, radiopharmaceutical development, PET scanner manufacturing, software integration, image reconstruction technologies, distribution, installation and clinical deployment in hospitals, diagnostic imaging centers, research institutions and specialty healthcare facilities. The report segments the market by Product Type (Full-Ring PET Scanners, Partial-Ring PET Scanners), Modality (Stand-Alone PET, PET/CT, PET/MRI), Radiotracer/Isotope (18F-Fluorodeoxyglucose (18F-FDG), 68Ga-Based Tracers (DOTATATE, PSMA), 82Rb & 13N-Ammonia (Cardiac), 64Cu & Zirconium-89 Immuno-PET), Application (Oncology, Cardiology, Neurology, Inflammation, Others), and End User (Hospitals, Diagnostic Imaging Centres, Others). The report examines the regional market dynamics of North America, Europe, Asia Pacific and LAMEA. It evaluates the influence of healthcare infrastructure, adoption of molecular imaging, cancer burden, radiopharmaceutical production capabilities, reimbursement frameworks and regulatory environments on regional market growth. The report also tracks developments in digital PET technology, AI-assisted image reconstruction, total-body PET systems, hybrid imaging platforms, theranostics and precision medicine that continue to redefine the competitive landscape of the PET imaging industry.

Research Methodology The study comprises of extensive primary and secondary research to provide reliable market intelligence and robust long term forecasting. Primary research was conducted by means of structured interviews with manufacturers of PET scanners, producers of radiopharmaceuticals, physicians in nuclear medicine, radiologists, oncologists, healthcare administrators, operators of imaging centers, regulatory experts and industry consultants in major global markets. Secondary research uses published information from international healthcare organisations, government agencies, annual reports, investor presentations, scientific journals, regulatory databases, nuclear medicine associations and authenticated market intelligence sources. Market estimates are developed through top-down and bottom-up approaches and validated by data triangulation to ensure accuracy of the data across all market segments and regional segments. Forecast models consider historical imaging procedure volumes, cancer incidence, healthcare expenditure, radiotracer uptake, reimbursement policies, demographic trends, macroeconomic indicators and technological innovation. Competitive benchmarking profiles the product portfolios, detector technologies, software capabilities, R&D investments, strategic partnerships, regulatory approvals, manufacturing capabilities, and geographic presence of key market players to provide a complete picture of the changing competitive landscape within the global Positron Emission Tomography (PET) Market.

Key Market Segments

By Product Type:

Full-Ring PET Scanners

Partial-Ring PET Scanners

By Modality:

Stand-Alone PET

PET/CT

PET/MRI

By Radiotracer / Isotope:

18F-Fluorodeoxyglucose (18F-FDG)

68Ga-Based Tracers (DOTATATE, PSMA)

82Rb & 13N-Ammonia (Cardiac)

64Cu & Zirconium-89 Immuno-PET

By Application:

Oncology

Cardiology

Neurology

Inflammation

Others

By End User:

Hospitals

Diagnostic Imaging Centres

Others

Key Market Players

Advanced Cyclotron Systems Inc.

Eckert & Ziegler

GE HealthCare

IBA Radiopharma Solutions

Koninklijke Philips N.V.

Sumitomo Heavy Industries

Neusoft Medical Systems

Positron Corporation

Shimadzu Corporation

Siemens Healthineers

Industry Trends

• Artificial intelligence (AI) is transforming positron emission tomography through its application to image reconstruction, lesion detection, automated quantification, workflow optimization and diagnostic accuracy. AI-assisted PET analysis leads to quicker image processing, reduced scan times and improved clinical decision-making in oncology, neurology and cardiology.
• Hybrid imaging modalities are still prevalent in clinical practice with PET/CT and PET/MRI systems providing integrated anatomical and functional imaging in a single examination. The increasing use of hybrid modalities enhances disease staging, treatment planning, assessment of therapy response and applications in precision medicine.
• NoThe creation of new radiopharmaceuticals is expanding the clinical uses of PET imaging beyond its traditional application in oncology. The use of 68Ga-PSMA, 68Ga-DOTATATE, 64Cu and Zirconium-89-based tracers is growing to allow targeted molecular imaging for prostate cancer, neuroendocrine tumours, immunotherapy monitoring and personalised treatment selection.
• Theranostics is a rapidly growing field in nuclear medicine that combines diagnostic PET imaging with targeted radionuclide therapy. Diagnostic imaging and therapeutic radiopharmaceuticals, combined, are improving patient selection, treatment monitoring and personalised cancer management.
• Digital PET detector technologies enhance the sensitivity, spatial resolution, timing performance, and quantitative accuracy of scanners. Development of more sophisticated detector architectures is providing improved image quality at lower radiotracer doses and shorter acquisition times, which improves patient comfort and clinical efficiency.
• Total-body PET imaging is becoming increasingly popular as next-generation systems offer much higher sensitivity, the ability to perform whole-body dynamic imaging, lower radiation dose, and better visualisation of disease progression. These technologies are expected to improve research applications and precision diagnostics in the years to come.
• The growing need for PET imaging is spurred by precision oncology and the application of molecular imaging biomarkers for personalised treatment planning, early evaluation of therapeutic response and disease recurrence. PET is being increasingly incorporated into multidisciplinary cancer care pathways and precision medicine programmes.
• The expansion of infrastructure for cyclotron and manufacturing capacity for radiopharmaceuticals is enhancing the availability of PET tracers across emerging healthcare markets. Investments in regional radiopharmacies and isotope production facilities are improving access to advanced molecular imaging services.
• Automation in radiopharmaceutical production, dose dispensing and quality control is enhancing the operational efficiency, regulatory compliance and production consistency to cater to the growing global demand for PET imaging procedures.
• Innovation in molecular imaging continues to accelerate through strategic collaborations among imaging equipment manufacturers, radiopharmaceutical companies, academic research institutions, healthcare providers, and biotechnology firms. "Investments in AI-enabled imaging platforms, novel radiotracers, digital PET systems, and precision diagnostics are expected to drive long-term growth of the global positron emission tomography market.
  • Market Determinants
• Rising Global Burden of Cancer and Chronic Diseases: The increasing prevalence of cancer, cardiovascular diseases, neurological disorders, and inflammatory conditions is a primary driver of the positron emission tomography (PET) market. PET imaging enables early disease detection, accurate staging, treatment planning, and therapy response monitoring, making it an essential component of modern precision diagnostics. According to the World Health Organization (WHO), cancer remains one of the leading causes of death worldwide, driving sustained demand for advanced molecular imaging technologies.
• Growing Adoption of Precision Medicine and Molecular Imaging: Healthcare providers are increasingly utilizing PET imaging to support personalized treatment strategies by evaluating disease biology at the molecular level. The expanding use of targeted radiotracers, companion diagnostics, and theranostic approaches is significantly increasing the clinical value of PET across oncology, neurology, cardiology, and other specialty areas.
• Technological Advancements in Hybrid Imaging Systems: Continuous innovation in PET/CT, PET/MRI, digital detector technology, artificial intelligence-assisted image reconstruction, and total-body PET systems is improving image quality, diagnostic confidence, workflow efficiency, and patient outcomes. These advancements are encouraging healthcare facilities to upgrade imaging infrastructure and expand molecular imaging capabilities.
• Expansion of Radiopharmaceutical Development: Ongoing development of novel radiotracers, including 68Ga-based tracers, 64Cu, Zirconium-89, and other targeted imaging agents, is broadening the clinical applications of PET beyond conventional FDG imaging. These innovations are supporting precision oncology, neuroimaging, cardiovascular diagnostics, and immunotherapy monitoring, creating new opportunities for market growth.
• High Capital Investment and Operating Costs: PET imaging systems, cyclotrons, radiopharmaceutical production facilities, and supporting infrastructure require substantial capital investment. High equipment acquisition costs, maintenance expenses, isotope production requirements, and specialized workforce needs may limit adoption, particularly among smaller healthcare providers and institutions in developing regions.
• Limited Availability of Radiopharmaceutical Infrastructure: The short half-life of many PET isotopes requires reliable cyclotron facilities, specialized radiopharmacies, and efficient distribution networks. Limited availability of isotope production infrastructure, regulatory challenges, and logistical constraints in certain regions may restrict access to PET imaging services and slow market expansion.

Opportunity Mapping Based on Market Trends

• Expansion of Precision Oncology and Theranostics: The growing adoption of precision oncology is creating significant opportunities for PET imaging. Increasing use of targeted radiotracers, companion diagnostics, and theranostic approaches enables personalized treatment selection, early assessment of therapeutic response, and disease monitoring. Manufacturers developing advanced PET technologies and novel radiopharmaceuticals are well positioned to benefit from the expanding role of molecular imaging in cancer care.
• Advancements in Artificial Intelligence and Digital PET Technologies: Rapid progress in artificial intelligence (AI), deep learning, digital detector technology, and automated image reconstruction is creating new growth opportunities across the PET market. AI-powered imaging platforms improve diagnostic accuracy, reduce scan times, optimize workflow efficiency, and support quantitative image analysis, enhancing the value proposition of PET systems for healthcare providers.
• Increasing Development of Novel Radiopharmaceuticals: Continuous innovation in targeted PET tracers, including 68Ga-based tracers, 64Cu, Zirconium-89, and emerging immuno-PET agents, is expanding clinical applications beyond conventional oncology. Growing research in neurodegenerative diseases, cardiovascular disorders, inflammatory diseases, and immunotherapy monitoring is expected to create substantial opportunities for radiopharmaceutical manufacturers and imaging providers.
• Expansion of Molecular Imaging Infrastructure Across Emerging Economies: Rising investments in healthcare infrastructure, cyclotron facilities, radiopharmacies, diagnostic imaging centers, and nuclear medicine programs across Asia Pacific, Latin America, the Middle East, and Africa are creating favorable conditions for market expansion. Government support for advanced cancer diagnostics, increasing healthcare expenditure, and improving access to precision medicine are expected to generate long-term growth opportunities for PET equipment manufacturers and radiopharmaceutical suppliers.

Value-Creating Segments and Growth Pockets

By Product Type, the Global Positron Emission Tomography (PET) Market is segmented into Full-Ring PET Scanners and Partial-Ring PET Scanners.

The Full-Ring PET Scanners are expected to have the higher market share of 72.8% in 2025. The segment is driven by superior detector sensitivity, better spatial resolution, faster acquisition times and better quantitative accuracy. The ongoing strong market demand is fueled by their extensive use in hospitals and advanced diagnostic imaging centers for the applications of oncology, cardiology, and neurology.

The Partial-Ring PET Scanners segment is expected to record the highest CAGR of 4.1% during the forecast period 2026-2036. This growth is driven by the rising demand for affordable molecular imaging systems, growing installations of PET scanners in mid-sized healthcare facilities, and continued innovation in detector technology to enhance imaging performance and reduce the total cost of the system.

By Modality, the Global Positron Emission Tomography (PET) Market is segmented into Stand-Alone PET, PET/CT, and PET/MRI.

The PET/CT is anticipated to lead the market with an estimated share of 76.2% in 2025. The segment is driven by its ability to combine functional and anatomical imaging in a single examination, allowing for highly accurate detection, staging, treatment planning and therapy monitoring across a range of clinical specialties. Broad clinical acceptance and established reimbursement further strengthen its leading position in the market.

The PET/MRI is expected to grow at the highest CAGR of 5.3% over the forecast period of 2026-2036, driven by its enhanced soft-tissue contrast, lower radiation exposure, increasing use in neurology and pediatrics, and growing adoption in precision oncology and advanced research settings.

By Radiotracer / Isotope, the Global Positron Emission Tomography (PET) Market is segmented into 18F-Fluorodeoxyglucose (18F-FDG), 68Ga-Based Tracers (DOTATATE, PSMA), 82Rb & 13N-Ammonia (Cardiac), and 64Cu & Zirconium-89 Immuno-PET.

18F-Fluorodeoxyglucose (18F-FDG) is projected to dominate the market with a share of 68.7% in 2025. The segment is underpinned by its robust clinical utility in oncology, cardiology and neurology, broad regulatory approvals, standardized imaging protocols and high availability across nuclear medicine facilities globally.

Ga-Based Tracers (DOTATATE & PSMA) are anticipated to record the fastest CAGR of 6.2% during 2026-2036 owing to increasing adoption of targeted molecular imaging for prostate cancer and neuroendocrine tumors, growing theranostic applications, and ongoing development of precision oncology treatment pathways.

By Application, the Global Positron Emission Tomography (PET) Market is segmented into Oncology, Cardiology, Neurology, Inflammation, and Others.

Oncology is projected to dominate the market with an estimated share of 63.9% in 2025. The dominance of the segment is attributed to the high use of PET imaging in cancer detection, staging, treatment response assessment, recurrence monitoring, and personalized treatment planning. The sustained demand is driven by the increasing global cancer burden and the adoption of precision oncology.

Neurology is expected to register the fastest CAGR of 4.8% during the forecast period of 2026-2036. This growth is driven by the increasing prevalence of Alzheimer's disease, Parkinson's disease, epilepsy, dementia, and other neurodegenerative disorders, where molecular brain imaging is playing a vital role in diagnosis.

By End User, the Global Positron Emission Tomography (PET) Market is segmented into Hospitals, Diagnostic Imaging Centres, and Others.

Hospitals are expected to dominate the market with an estimated share of 66.1% in 2025. Segment growth is driven by high patient volumes, extensive oncology services, integrated nuclear medicine departments, multidisciplinary clinical teams and increased capital investment in advanced hybrid imaging technologies.

Diagnostic Imaging Centres are expected to record the highest CAGR of 4.4% during 2026-2036. This can be attributed to the increasing demand for outpatient diagnostic services, growth of private imaging networks, enhanced access to advanced molecular imaging technologies, and rising referrals for specialized PET imaging procedures.

Regional Market Assessment

North America

North America is expected to lead the global positron emission tomography (PET) market with a share of 39.5% in 2025. The leadership of the region is driven by advanced healthcare infrastructure, high adoption of hybrid imaging technologies, high availability of radiopharmaceuticals and favorable reimbursement policies for molecular imaging procedures. The United States leads the regional market owing to significant investments in precision oncology, high adoption of PET/CT systems, robust nuclear medicine infrastructure and the presence of prominent imaging equipment and radiopharmaceutical manufacturers. Continuous advancements in AI-assisted imaging and theranostic applications also bolster growth of the regional market.

Europe

Europe is a major market for PET imaging due to strong nuclear medicine programs, the increase in cancer screening programs and heavy investments in molecular diagnostics. The uptake of PET/CT and PET/MRI systems for oncology, cardiology and neurology applications continues to grow in Germany, France, the United Kingdom, Italy and the Netherlands. Rising development of novel radiotracers and increasing precision medicine initiatives are further supporting the regional market growth.

Asia Pacific

Asia Pacific is expected to witness the highest CAGR of 4.6% during the forecast period. Growing healthcare infrastructure, increasing cancer incidence, increasing investments in diagnostic imaging technologies, and increasing availability of cyclotrons and radiopharmaceutical production facilities in China, India, Japan, South Korea, and Southeast Asia are factors driving the growth of this market. The market in the region is projected to grow due to government support for cancer care modernization, better access to healthcare and enhanced nuclear medicine capabilities.

LAMEA

LAMEA is emerging as a potential market for PET imaging owing to increasing investments in advanced diagnostic infrastructure, increasing oncology care, and increasing access to nuclear medicine services. Brazil, Mexico, Saudi Arabia, the United Arab Emirates, and South Africa are investing in PET imaging systems, radiopharmaceutical production, and specialized cancer treatment centers to improve precision diagnostics and patient outcomes. Long-term regional growth will be driven by increased healthcare spending and the modernization of medical imaging infrastructure.

Recent Developments

• May 2025: GE HealthCare expanded its digital PET imaging portfolio by introducing advanced AI-assisted image reconstruction technologies designed to improve image quality, reduce scan times, and enhance diagnostic confidence.
• March 2025: Siemens Healthineers strengthened its molecular imaging portfolio through enhancements to its PET/CT platforms, integrating artificial intelligence and advanced workflow automation to improve clinical efficiency.
• October 2024: IBA Radiopharma Solutions expanded its radiopharmaceutical production capabilities by introducing advanced cyclotron technologies and automated radiochemistry solutions to improve isotope availability for molecular imaging applications.
• July 2024: Koninklijke Philips N.V. enhanced its hybrid molecular imaging solutions with new software upgrades supporting faster image processing, improved quantitative analysis, and optimized oncology workflow integration.

Critical Business Questions Addressed

How will the Global Positron Emission Tomography (PET) Market evolve through 2036?

The report evaluates long-term market growth, molecular imaging adoption, radiopharmaceutical innovation, hybrid imaging advancements, artificial intelligence integration, and precision medicine trends shaping future demand for PET technologies.

Which product type, modality, radiotracer, application, and end-user segments will generate the greatest commercial opportunities?

The study identifies the dominant and fastest-growing market segments, enabling imaging equipment manufacturers, radiopharmaceutical companies, healthcare providers, and investors to prioritize strategic investments.

What are the primary factors driving market expansion?

The report analyzes the influence of rising cancer prevalence, chronic disease burden, precision oncology, theranostics, hybrid imaging technologies, and radiotracer innovation on future market development.

Which regional markets present the strongest long-term investment potential?

The assessment compares healthcare infrastructure, nuclear medicine capabilities, reimbursement frameworks, radiopharmaceutical availability, and precision medicine adoption across major regions to identify the most attractive growth opportunities.

How can PET imaging companies strengthen their competitive position in the evolving industry?

The report examines strategic priorities including AI-enabled imaging, digital PET innovation, novel radiotracer development, cyclotron infrastructure expansion, strategic collaborations, and precision diagnostics to support long-term competitive advantage.

Beyond the Forecast

• The PET market will increasingly benefit from advances in artificial intelligence, digital detector technologies, total-body PET systems, novel radiopharmaceuticals, and theranostic medicine, enabling more accurate, personalized, and efficient molecular imaging.
• Rising global cancer incidence, expanding precision oncology programs, increasing adoption of targeted radiotracers, and growing investments in nuclear medicine infrastructure will continue to create substantial opportunities for PET equipment manufacturers and radiopharmaceutical suppliers across developed and emerging markets.
• As healthcare systems prioritize early disease detection, personalized treatment planning, and value-based care, companies investing in hybrid imaging technologies, advanced molecular diagnostics, AI-powered image analysis, and next-generation radiopharmaceuticals will be well positioned to capitalize on long-term growth opportunities in the global positron emission tomography (PET) market through 2036.